Assessing the Potential for Improved Joint Health and Wellbeing by Providing a Whole Salmon Oil With Undenatured Type II Collagen Compared to Type II Collagen Alone
Condition(s) studied
Investigational drug(s) / intervention(s)
Undenatured collagen: Natural type II collagen
Whole salmon oil: OmeGo
Study summary
This study evaluates the combination of NT-II® salmon undenatured type II collagen with OmeGo® salmon oil in adults who regularly experience knee discomfort. The aim is to assess whether participants experience faster and greater improvements in joint health with the combination than undenatured type II collagen alone .
Eligibility
Primary outcome measure(s)
- Change in knee pain measured by visual analogue scale (VAS) score — From baseline (day 0) to day 5
Visual analog scale score of knee pain scored from 0 representing no pain to 100 representing the worst pain imaginable - Change in KOOS (Knee Injury and Osteoarthritis Outcome Score) Quality of Life (QoL) score — From baseline (day 0) to end of study (day 30)
Measure from baseline (day 0) to end of study (day 30). The KOOS QoL score assesses the extent to which knee discomfort is affecting lifestyle and daily enjoyment with 0 representing extreme knee-related QoL problems and 100 representing no knee problems at all. KOOS is designed for assessing milder forms of joint discomfort in active subjects.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Alethios Inc. | San Francisco | California |
More Hofseth Biocare ASA trials in the USA
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07875101 on ClinicalTrials.gov ↗ ← All trials in the USA